CLAIM AMENDMENTS

30. (Previously Presented) A method for the treatment and/or amelioration of one or more symptoms of bacterial vaginosis, comprising administering to an individual having one or more symptoms of bacterial vaginosis an effective amount of a medicament comprising a saccharide wherein the medicament includes less than 10^5 bacteria per dosage, and

a) wherein the medicament comprises at least 75 percent by weight of said saccharide or

b) wherein the medicament is a gel or suspension comprising at least 40 % by weight of said saccharide, thereby treating and/or ameliorating symptoms of bacterial vaginosis.

31. (Previously Presented) The method according to claim 30, wherein one symptom is unpleasant vaginal odour.

32. (Previously Presented) The method according to claim 30, wherein a symptom is pruritus of vulva.

33. (Previously Presented) The method according to claim 30, wherein the saccharide is substantially not fermented by Gardnerella vaginalis.

34. (Previously Presented) The method according to claim 30, wherein the saccharide is selected from a disaccharide and a monosaccharide.

35. (Previously Presented) The method according to claim 30, wherein the saccharide is selected from lactose and saccharose.

36. – 37. (Canceled)

38. (Previously Presented) The method according to claim 30, wherein the medicament comprises at least 50 percent by weight of saccharide.

39. (Previously Presented) The method according to claim 30, wherein the medicament comprises at least 75 percent by weight of saccharide.

40. (Previously Presented) The method according to claim 30, wherein the bacterial vaginosis is caused by bacteria selected from Gardnerella vaginalis, Gram negative rods, and Mycoplasma hominis.

41. (Previously Presented) The method according to claim 40, wherein the bacterial vaginosis is caused by bacteria selected from anaerobic Gram negative rods.

42. (Previously Presented) The method according to claim 30, wherein the medicament is formulated for topical application.

43. (Previously Presented) The method according to claim 30, wherein the medicament is in the form of a vaginal suppository gel.

44. (Previously Presented) The method according to claim 30, wherein the medicament is in the form of a vaginal capsule.

45. (Previously Presented) The method according to claim 30, wherein the medicament is in the form of a vaginal tablet.

46. (Previously Presented) The method according to claim 30, wherein the medicament is in the form of a suspension.

47. (Previously Presented) The method according to claim 30, wherein a dosage unit is from 10 mg to 10 g of medicament.

48. (Previously Presented) The method according to claim 30, wherein a dosage unit is from 1-5 g of medicament.

49. (Previously Presented) The method according to claim 30, wherein the medicament further includes an effective amount of an anti-fungal agent.

50. (Previously Presented) The method according to claim 49, wherein the anti-fungal agent is selected from ketoconazole, terconazole, itraconazole, and fluconazole.

51. (Previously Presented) The method according to claim 30, wherein the medicament further includes an effective amount of an anti-bacterial agent.

52. (Previously Presented) The method according to claim 51, wherein the anti-bacterial agent is selected from metronidazole and clindamycin.

53. (Currently Amended) A pharmaceutical composition for vaginal application, ~~comprising a saccharide,~~ the composition including less than 10^5 bacteria per dosage, said composition consisting essentially of: [[and]]

a) ~~wherein said~~ a saccharide ~~constitutes~~ constituting at least 75 percent by weight of said pharmaceutical composition or,

b) wherein the pharmaceutical composition is a gel or suspension, a ~~and said~~ saccharide ~~constitutes~~ constituting at least 40 percent [[%]] by weight of said pharmaceutical composition, and ~~wherein said pharmaceutical composition does not contain progesterone.~~

c) optionally one or more pharmaceutically acceptable additives, carriers and/or preservatives.

54. (Previously Presented) A kit-of-parts comprising the pharmaceutical composition as defined in claim 53 and an anti-fungal agent and/or an anti-bacterial agent for simultaneous, sequential or separate use.

55. (Previously Presented) A kit-of-parts comprising the pharmaceutical composition as defined in claim 53 and at least one pH measurement means, for measuring vaginal pH.

56. (Previously Presented) The pharmaceutical composition according to claim 53, wherein the composition further includes an effective amount of an anti-fungal agent or an anti-bacterial agent.

57. (Previously Presented) The pharmaceutical composition according to claim 53, wherein said saccharide is the essential active component.

58. (Canceled)

59. (Previously Presented) A method for reducing vaginal pH to below 4.7, comprising administering to an individual having one or more symptoms of bacterial vaginosis an effective amount of a medicament comprising a saccharide, the medicament including less than 10^5 bacteria per dosage, and

a) wherein the medicament comprises at least 75 percent by weight of said saccharide or

b) wherein the medicament is a gel or suspension comprising at least 40 % by weight of said saccharide, thereby reducing the vaginal pH to below 4.7.

60. (Previously Presented) The method of claim 59 wherein the vaginal pH is reduced to below 4.5.

61. (Previously Presented) The method of claim 59 further comprising measuring said vaginal pH subsequent to said administering.

62. – 63. (Canceled)

64. (New) The pharmaceutical composition of claim 53, wherein the one or more pharmaceutically acceptable additives and carriers of c) is selected from the group consisting of: polyethylene glycols, glycerol, agar agar, carrageenan, modified starches, stearates and water.

65. (New) The pharmaceutical composition of claim 64, wherein the pharmaceutically acceptable additive is magnesium stearate or sodium stearate.

66. (New) A pharmaceutical composition for vaginal application, comprising a saccharide, the composition including less than 10^5 bacteria per dosage and an anti-fungal and/or anti-bacterial agent, and

a) wherein said saccharide constitutes at least 75 percent by weight of said pharmaceutical composition or,

b) wherein the pharmaceutical composition is a gel or suspension and said saccharide constitutes at least 40 percent by weight of said pharmaceutical composition.